Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alutard-sq
- Development stage
- Phase 4
- Lead developer
- ALK Abelló
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Alutard-SQ is a range of allergen-specific subcutaneous immunotherapy (SCIT) products developed by ALK-Abelló. It consists of standardized allergen extracts (such as those from pollens, house dust mites, or animal dander) that are adsorbed onto aluminum hydroxide to create a depot for slow release. This formulation is designed to provide a prolonged immunological stimulus while minimizing the risk of systemic allergic reactions. The primary mechanism of action involves allergen-specific immunotherapy (AIT), which induces a shift in the immune response from a pro-allergic Th2 profile to a Th1 and regulatory T-cell (Treg) profile. This shift is characterized by the production of blocking antibodies, specifically allergen-specific IgG4, and a reduction in the activation and recruitment of mast cells, basophils, and eosinophils. Alutard-SQ is indicated for the treatment of IgE-mediated allergic diseases, including allergic rhinitis, allergic conjunctivitis, and allergic asthma, particularly when symptomatic treatment is insufficient.
- Brand names
- Alutard-SQAlutard SQAlutardAluTard 225AluTard225AluTard-225Antuoda
- Other names
- Alutard-SQAlutard SQAlutardAluTard 225AluTard225AluTard-225Antuoda安脱达
02
Targets
HMGB1 (High mobility group protein B1)NF-κBTLR4 (Toll-like receptor 4)A. annua-specific IgE (Artemisia annua-specific immunoglobulin E)sIgG4 (Allergen-specific immunoglobulin G4)γδ TCR (T-cell receptor)
Beyond the preview
Go deeper on alutard-sq.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alutard-sq.